1. The Abstract states “61% of training grants” to medicine and “1%” to C/SOPs; the text says “67% or $478.7 million out of a total of $710 million”; Table FY24 reports total all institutions as **$781,615,460** and C/SOPs as **1.20%**. Which denominator is correct? If $710M is correct, C/SOPs should be ~1.33%, not 1.20%.
2. Results describes “26 institutional T32 training grants,” but the Table is titled “NIH institutional training awards” and Methods mention T32, T35, and other T-series. Are all counts and dollar totals restricted to T32? If not, T32-specific conclusions are unsupported.
3. The statement that C/SOP funding “stayed reasonably constant” conflicts with Table: C/SOP funding rose from $7.63M (FY20) to $11.22M (FY22) then fell to $9.42M (FY24); a 23% increase then 16% decrease.
4. Does the ACPE standard limiting extended-degree pathways to 150% of the traditional PharmD actually apply to PharmD/PhD programs where the PhD is not part of the ACPE-accredited PharmD? If not, this barrier is overstated.
5. Absolute claim about pharmacy residents!!! “We found no other NIH funding mechanisms designed to support research by pharmacy residents” needs support; did the search include K12, LRP, R38, or other career-development mechanisms?
